Nasdaq

Neuren’s NNZ-2591 Shows Promise for Pitt Hopkins

Neuren Pharmaceuticals Limited (AU:NEU) has released an update. Neuren Pharmaceuticals Limited has announced promising Phase 2 clinical trial results for NNZ-2591, showing significant improvements in ...
Yahoo Finance

Neuren Pharmaceuticals’ NNZ-2591 shows promise in trial for Pitt Hopkins syndrome

Australian biopharmaceutical company Neuren Pharmaceuticals has announced positive top-line data from its Phase II trial of NNZ-2591, a treatment for children with Pitt Hopkins syndrome (PTHS). PTHS ...
Nasdaq

Neuren's NNZ-259 Phase 2 Trial Demonstrates Significant Improvements In Pitt Hopkins Syndrome

(RTTNews) - Neuren Pharmaceuticals (NEU.AX) announced positive results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement ...
Business Wire

Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ...
Kaleido Scope

Newsom completes Phase 2 clinical trial of a novel drug for Pitt-Hopkins Syndrome

Principal Investigator Cassandra Newsom, Psy.D., director of the Translational Research Core in Autism and Neurodevelopment of Civitan International Research Center, has completed participation in ...
Pharmabiz

Neuren Phrma announces positive results from phase 2 trial of NNZ-2591 in children with Pitt Hopkins syndrome

Neuren Pharmaceuticals, a company develops new drug therapies to treat multiple serious neurological disorders, announced top-line results from its phase 2 clinical trial of NNZ-2591 in children with ...
Medindia

Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome

- Clinical Global Impression of Improvement (CGI-I) - mean score of 2.6, with 9 out of 11 children showing improvement assessed by clinicians- Caregiver Overall Impression of Change (CIC) – mean score ...
BioWorld

Australia’s Neuren raises AU$20M to advance NNZ-2591 to the clinic in three orphan indications

PERTH, Australia – Melbourne-based Neuren Pharmaceuticals Ltd. will be able to progress NNZ-2591 to the clinic for three orphan indications after raising AU$20 million (US$13.75 million) in a ...